MedTrace Logo

An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer

NCT04777071 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2026-01-09

No results posted yet for this study

Summary

This trial studies how well 68Ga-PSMA-11 PET scan works in imaging patients with prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET may find and diagnose prostate cancer and improve monitoring of treatment response.

Conditions

  • Biochemically Recurrent Prostate Carcinoma
  • Metastatic Castration-Resistant Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Stage IIC Prostate Cancer AJCC v8
  • Stage III Prostate Cancer AJCC v8
  • Stage IVB Prostate Cancer AJCC v8

Interventions

PROCEDURE

Computed Tomography

Undergo PET/CT scan

DRUG

Gallium Ga 68 Gozetotide

Given IV

PROCEDURE

Positron Emission Tomography

Undergo PET/CT scan

PROCEDURE

Magnetic Resonance Imaging

Undergo PET/MR scan

PROCEDURE

Bone Scan

Undergo bone scan

OTHER

Electronic Health Record Review

Ancillary studies

Sponsors & Collaborators

Principal Investigators

  • Delphine L. Chen, M.D. · Fred Hutch/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-17
Primary Completion
2025-07-15
Completion
2030-07-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04777071 on ClinicalTrials.gov